NASDAQ: GILD - Gilead Sciences

Yield per half year: -22.91%
Sector: Healthcare

Download the report: word Word , pdf PDF

1. Summary

Advantages

  • Positive review Dividends (3.7%) are higher than the sector average (2.19%).
  • Positive review The stock's return over the last year (-13.92%) is higher than the sector average (-80.3%).
  • Positive review Current debt level 40.22% is below 100% and has decreased over 5 years from 42.9%.
  • Positive review The company's current efficiency (ROE=25.77%) is higher than the sector average (ROE=11.93%)

Disadvantages

  • Negative review Price (66.59 $) is higher than fair price (42.21 $)

2. Share price and performance

2.1. Share price

2.2. News

2.3. Market efficiency

Gilead Sciences Healthcare Index
7 days 0% -100% -2.2%
90 days -2.2% -100% -15.3%
1 year -13.9% -80.3% -0.9%

Positive review GILD vs Sector: Gilead Sciences has outperformed the "Healthcare" sector by 66.38% over the past year.

Negative review GILD vs Market: Gilead Sciences has significantly underperformed the market by -12.98% over the past year.

Positive review Stable price: GILD is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.

Long period: GILD with weekly volatility of -0.2677% over the past year.

3. Summary of the report

3.1. General

P/E: 17.69
P/S: 3.7

3.2. Revenue

EPS 4.5
ROE 25.77%
ROA 9.04%
ROIC 11.06%
Ebitda margin 28.05%

4. Fundamental Analysis

4.1. Stock price and price forecast

The fair price is calculated taking into account the Central Bank refinancing rate and earnings per share (EPS)

Negative review Above fair price: The current price (66.59 $) is higher than the fair price (42.21 $).

Negative review Price is higher than fair: The current price (66.59 $) is 36.6% higher than the fair price.

4.2. P/E

Positive review P/E vs Sector: The company's P/E (17.69) is lower than that of the sector as a whole (86.72).

Positive review P/E vs Market: The company's P/E (17.69) is lower than that of the market as a whole (54.77).

4.2.1 P/E Similar companies

4.3. P/BV

Positive review P/BV vs Sector: The company's P/BV (4.41) is lower than that of the sector as a whole (49.71).

Negative review P/BV vs Market: The company's P/BV (4.41) is higher than that of the market as a whole (2.3).

4.3.1 P/BV Similar companies

4.4. P/S

Positive review P/S vs Sector: The company's P/S indicator (3.7) is lower than that of the sector as a whole (49.73).

Positive review P/S vs Market: The company's P/S indicator (3.7) is lower than that of the market as a whole (9.99).

4.4.1 P/S Similar companies

4.5. EV/Ebitda

Positive review EV/Ebitda vs Sector: The company's EV/Ebitda (15.66) is lower than that of the sector as a whole (61.59).

Positive review EV/Ebitda vs Market: The company's EV/Ebitda (15.66) is lower than that of the market as a whole (22.26).

5. Profitability

5.1. Profitability and revenue

5.2. Earnings per share - EPS

5.3. Past profitability Ebitda

Positive review Yield Trend: Rising and has grown by 1.039% over the last 5 years.

Negative review Earnings Slowdown: The last year's return (0%) is below the 5-year average return (1.039%).

Positive review Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-9.42%).

5.4. ROE

Positive review ROE vs Sector: The company's ROE (25.77%) is higher than that of the sector as a whole (11.93%).

Negative review ROE vs Market: The company's ROE (25.77%) is lower than that of the market as a whole (31.8%).

5.5. ROA

Positive review ROA vs Sector: The company's ROA (9.04%) is higher than that of the sector as a whole (7.1%).

Positive review ROA vs Market: The company's ROA (9.04%) is higher than that of the market as a whole (7.12%).

5.6. ROIC

Negative review ROIC vs Sector: The company's ROIC (11.06%) is lower than that of the sector as a whole (13.31%).

Positive review ROIC vs Market: The company's ROIC (11.06%) is higher than that of the market as a whole (10.68%).

6. Finance

6.1. Assets and debt

Positive review Debt level: (40.22%) is quite low in relation to assets.

Positive review Debt reduction: over 5 years, the debt has decreased from 42.9% to 40.22%.

Negative review Excess of debt: The debt is not covered by net income, percentage 440.74%.

6.2. Profit growth and share price

7. Dividends

7.1. Dividend yield vs Market

Positive review High yield: The dividend yield of the company 3.7% is higher than the average for the sector '2.19%.

7.2. Stability and increase in payments

Positive review Dividend stability: The company's dividend yield 3.7% has been steadily paid over the past 7 years, DSI=0.93.

Positive review Dividend growth: Company's dividend yield 3.7% has been growing over the last 5 years. Growth over 13 years.

7.3. Payout percentage

Positive review Dividend Coverage: Current payments from income (67.24%) are at a comfortable level.

8. Insider trades

8.1. Insider trading

Negative review Insider Selling More insider purchases by 100% over the last 3 months.

8.2. Latest transactions

Transaction date Insider Type Price Volume Quantity
01.07.2024 Parsey Merdad
Chief Medical Officer
Sale 68.63 137 260 2000
29.02.2024 Parsey Merdad
Chief Medical Officer
Sale 72.74 598 650 8230
28.02.2024 Parsey Merdad
Chief Medical Officer
Sale 73.18 146 360 2000
16.01.2024 Dickinson Andrew D
Chief Financial Officer
Sale 85.78 428 900 5000
09.01.2024 Mercier Johanna
Chief Commercial Officer
Sale 85.23 702 466 8242

Оплатите подписку

Больше функциональности и данных для анализа компаний и портфеля доступно по подписке

9. Stocks forum Gilead Sciences